HDAC3 is critical in tumor development and therapeutic resistance in Kras -mutant non–small cell lung cancer
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
HDAC3 is one of the main targets of histone deacetylase (HDAC) inhibitors in clinical development as cancer therapies, yet the in vivo role of HDAC3 in solid tumors is unknown. We identified a critical role for HDAC3 in Kras -mutant lung cancer. Using genetically engineered mouse models (GEMMs), we found that HDAC3 is required for lung tumor growth in vivo. HDAC3 was found to direct and enhance the transcription effects of the lung cancer lineage transcription factor NKX2-1 to mediate expression of a common set of target genes. We identified FGFR1 as a critical previously unidentified target of HDAC3. Leveraging this, we identified that an HDAC3-dependent transcriptional cassette becomes hyperactivated as Kras/LKB1 -mutant cells develop resistance to the MEK inhibitor trametinib, and this can be reversed by treatment with the HDAC1/HDAC3 inhibitor entinostat. We found that the combination of entinostat plus trametinib treatment elicits therapeutic benefit in the Kras/LKB1 GEMM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908 · cited 1×
“1 image analysis software (Cambridge Research and Instrumentation), or QuPath software ( 80 ).”
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564 · cited 2×
“…waning, which has been conjectured to be due to limiting toxicity from current agents inhibiting multiple HDAC family members, as well as lack of insights into the optimal clinical contexts where HDAC inhibitors may synergize with other currently approved or in-develop-ment therapeutics ( 54 ).”
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR‐1
Lizcano, J. M., Göransson, O., Toth, R., Deak, M., Morrice, N. A., Boudeau, J., Hawley, S. A., Udd, L., Mäkelä, T. P., Hardie, D. G., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600110 · Cited by 1,381
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
Cancer Genome Atlas Research Network, Campbell, J. D., Alexandrov, A., Kim, J., Wala, J., Berger, A. H., Pedamallu, C. S., Shukla, S. A., Guo, G., Brooks, A. N., et al. (2016) · Nature Genetics · doi:10.1038/ng.3564 · Cited by 1,200
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019
The SMRT and N-CoR Corepressors Are Activating Cofactors for Histone Deacetylase 3
Guenther, M. G., Barak, O., & Lazar, M. A. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.18.6091-6101.2001 · Cited by 611
Shackelford, D. B., Abt, E., Gerken, L., Vasquez, D. S., Seki, A., Leblanc, M., Wei, L., Fishbein, M. C., Czernin, J., Mischel, P. S., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.008 · Cited by 585 · cited 2×
“Kras ( Kras LSLG12D/+ ; R26 LSL;luc/luc ), KL ( Kras LSLG12D/+ ; Lkb1 fl/fl ; R26 LSL;luc/luc ), KP ( Kras LSLG12D/+ ; p53 fl/fl ; R26 LSL;luc/luc ), and KPL ( Kras LSLG12D/+ ; Lkb1 fl/fl ; p53 fl/fl ; R26 LSL;luc/luc ) mice in FVB/n have been previously described ( 29 , 36 ).”
Self-citationEpigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Topper, M. J., Vaz, M., Chiappinelli, K. B., DeStefano Shields, C. E., Niknafs, N., Yen, R.-W. C., Wenzel, A., Hicks, J., Ballew, M., Stone, M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.022 · Cited by 537
Svensson, R. U., Parker, S. J., Eichner, L. J., Kolar, M. J., Wallace, M., Brun, S. N., Lombardo, P. S., Van Nostrand, J. L., Hutchins, A., Vera, L., et al. (2016) · Nature Medicine · doi:10.1038/nm.4181 · Cited by 536
Self-citationSuppression of lung adenocarcinoma progression by Nkx2-1
Winslow, M. M., Dayton, T. L., Verhaak, R. G. W., Kim-Kiselak, C., Snyder, E. L., Feldser, D. M., Hubbard, D. D., DuPage, M. J., Whittaker, C. A., Hoersch, S., et al. (2011) · Nature · doi:10.1038/nature09881 · Cited by 467
BRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance
Tasdemir, N., Banito, A., Roe, J.-S., Alonso-Curbelo, D., Camiolo, M., Tschaharganeh, D. F., Huang, C.-H., Aksoy, O., Bolden, J. E., Chen, C.-C., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0217 · Cited by 415
NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination
Ruscetti, M., Leibold, J., Bott, M. J., Fennell, M., Kulick, A., Salgado, N. R., Chen, C.-C., Ho, Y.-J., Sanchez-Rivera, F. J., Feucht, J., et al. (2018) · Science · doi:10.1126/science.aas9090 · Cited by 415
A combinatorial strategy for treating KRAS-mutant lung cancer
Manchado, E., Weissmueller, S., Morris, J. P., Chen, C.-C., Wullenkord, R., Lujambio, A., de Stanchina, E., Poirier, J. T., Gainor, J. F., Corcoran, R. B., et al. (2016) · Nature · doi:10.1038/nature18600 · Cited by 403
Orillion, A., Hashimoto, A., Damayanti, N., Shen, L., Adelaiye-Ogala, R., Arisa, S., Chintala, S., Ordentlich, P., Kao, C., Elzey, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0741 · Cited by 373
Hdac3 is essential for the maintenance of chromatin structure and genome stability
Bhaskara, S., Knutson, S. K., Jiang, G., Chandrasekharan, M. B., Wilson, A. J., Zheng, S., Yenamandra, A., Locke, K., Yuan, J.-L., Bonine-Summers, A. R., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.022 · Cited by 353
Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration
Sun, Z., Miller, R. A., Patel, R. T., Chen, J., Dhir, R., Wang, H., Zhang, D., Graham, M. J., Unterman, T. G., Shulman, G. I., et al. (2012) · Nature Medicine · doi:10.1038/nm.2744 · Cited by 335 · cited 1×
“…in brown adipose tissue causes mice to become hypothermic and succumb to acute cold exposure ( 20 ), but HDAC3 deletion in the liver induces hypertrophy and metabolic alterations ( 21 – 23 ), and the genes controlled by HDAC3 in each tissue are distinct and relate to tissue-specific functions.”
Epigenetic therapy inhibits metastases by disrupting premetastatic niches
Lu, Z., Zou, J., Li, S., Topper, M. J., Tao, Y., Zhang, H., Jiao, X., Xie, W., Kong, X., Vaz, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2054-x · Cited by 330
CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
Jiang, Y., Ortega-Molina, A., Geng, H., Ying, H.-Y., Hatzi, K., Parsa, S., McNally, D., Wang, L., Doane, A. S., Agirre, X., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0975 · Cited by 278
Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks
Knutson, S. K., Chyla, B. J., Amann, J. M., Bhaskara, S., Huppert, S. S., & Hiebert, S. W. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.51 · Cited by 271
Thyroid transcription factors in development, differentiation and disease
Fernández, L. P., López-Márquez, A., & Santisteban, P. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.186 · Cited by 258 · cited 1×
“Subsequent studies confirmed the requirement for NKX2-1 in proper lung and thyroid development, and NKX2-1 dysfunction is associated with human disease in these tissues ( 41 , 66 ).”
Integrative regulation of physiology by histone deacetylase 3
Emmett, M. J., & Lazar, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0076-0 · Cited by 202
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
Ny, L., Jespersen, H., Karlsson, J., Alsén, S., Filges, S., All-Eriksson, C., Andersson, B., Carneiro, A., Helgadottir, H., Levin, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25332-w · Cited by 177
The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC
Hollstein, P. E., Eichner, L. J., Brun, S. N., Kamireddy, A., Svensson, R. U., Vera, L. I., Ross, D. S., Rymoff, T. J., Hutchins, A., Galvez, H. M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1261 · Cited by 168 · cited 4×
“…kinases are most critical to LKB1 tumor suppressor function in the lung revealed that AMPK may not be as critical as originally hypothesized ( 29 ) and that two AMPK-related kinases, salt inducible kinase 1 (SIK1) and SIK3, are the most important for suppressing growth of lung tumors ( 30 , 31 ).”
InfluentialSelf-citationMondello, P., Tadros, S., Teater, M., Fontan, L., Chang, A. Y., Jain, N., Yang, H., Singh, S., Ying, H.-Y., Chu, C.-S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0116 · Cited by 167
KrasG12D and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung
Maeda, Y., Tsuchiya, T., Hao, H., Tompkins, D. H., Xu, Y., Mucenski, M. L., Du, L., Keiser, A. R., Fukazawa, T., Naomoto, Y., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64048 · Cited by 163
TBL1XR1 mutations drive extranodal lymphoma by inducing a pro-tumorigenic memory fate
Venturutti, L., Teater, M., Zhai, A., Chadburn, A., Babiker, L., Kim, D., Béguelin, W., Lee, T. C., Kim, Y., Chin, C. R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.049 · Cited by 127 · cited 2×
“Notably, however, recent studies have identified HDAC3 as playing a specific role in lymphomas ( 55 – 57 ), rhabdo-myosarcoma ( 58 ), melanomas ( 59 ), and pancreatic cancer ( 60 ) settings.”
An LKB1–SIK Axis Suppresses Lung Tumor Growth and Controls Differentiation
Murray, C. W., Brady, J. J., Tsai, M. K., Li, C., Winters, I. P., Tang, R., Andrejka, L., Ma, R. K., Kunder, C. A., Chu, P., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1237 · Cited by 111 · cited 1×
“…kinases are most critical to LKB1 tumor suppressor function in the lung revealed that AMPK may not be as critical as originally hypothesized ( 29 ) and that two AMPK-related kinases, salt inducible kinase 1 (SIK1) and SIK3, are the most important for suppressing growth of lung tumors ( 30 , 31 ).”
Maertens, O., Kuzmickas, R., Manchester, H. E., Emerson, C. E., Gavin, A. G., Guild, C. J., Wong, T. C., De Raedt, T., Bowman-Colin, C., Hatchi, E., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0879 · Cited by 95 · cited 3×
“Notably, however, recent studies have identified HDAC3 as playing a specific role in lymphomas ( 55 – 57 ), rhabdo-myosarcoma ( 58 ), melanomas ( 59 ), and pancreatic cancer ( 60 ) settings.”
Kaufman, J. M., Amann, J. M., Park, K., Arasada, R. R., Li, H., Shyr, Y., & Carbone, D. P. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000173 · Cited by 87
Entinostat induces antitumor immune responses through immune editing of tumor neoantigens
Truong, A. S., Zhou, M., Krishnan, B., Utsumi, T., Manocha, U., Stewart, K. G., Beck, W., Rose, T. L., Milowsky, M. I., He, X., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci138560 · Cited by 84
Cited by
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Shi, X., Hu, L., Huang, Y., Zhang, M.-F., Ying, X., Yuan, X., Wen, N., Lu, J., Zou, H., Tan, X., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2025.09.014 · Cited by 6
IPMK regulates HDAC3 activity and histone H4 acetylation in human cells
Sowd, G. A., Stivison, E. A., Chapagain, P., Hale, A. T., Poland, J. C., Rameh, L. E., & Blind, R. D. (2024) · doi:10.1101/2024.04.29.591660 · Cited by 6
Metadata
- Authors
- Eichner, L. J., Curtis, S. D., Brun, S. N., McGuire, C. K., Gushterova, I., Baumgart, J. T., Trefts, E., Ross, D. S., Rymoff, T. J., & Shaw, R. J.
- Venue
- Science Advances
- Published
- 2023-03-17
- Volume
- 9
- Issue
- 11
- Pages
- eadd3243-eadd3243
- ISSN
- 2375-2548 (ISSN-L)
- OpenAlex
- W4327697238
- Cited by
- 75
- References
- 32
- FWCI
- 5.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.